SEARCH:   Advanced

Blood, 15 September 2006, Vol. 108, No. 6, pp. 1972-1974. Prepublished online as a Blood First Edition Paper on May 25, 2006; DOI 10.1182/blood-2006-03-013177. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-03-013177v1 108/6/1972    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robin, M. Articles by Chomienne, C. Search for Related Content PubMed PubMed Citation Articles by Robin, M. Articles by Chomienne, C. Related Collections Immunobiology Neoplasia Oncogenes and Tumor Suppressors Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Brief report Frequent antibody production against RAR in both APL mice and patients Marie Robin, Juliette Andreu-Gallien, Marie-Helene Schlageter, Djaouida Bengoufa, Isabelle Guillemot, Katerina Pokorna, Carine Robert, Jerome Larghero, Philippe Rousselot, Emmanuel Raffoux, Herve Dombret, Pierre Fenaux, Marika Pla, Dominique Charron, Rose-Ann Padua, and Christine Chomienne From the Institut National de la Santé et de la Recherche Médicale (INSERM), Unité mixte de recherche (UMR) S 718, Paris; Université Paris 7, Institut Universitaire d'Hématologie (IUH), UMR S 718, Paris; Laboratoire d'Immunologie et d'Histocompatibilité, Assistance Publique–Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Paris; Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris; Service d'Hématologie, AP-HP, Hôpital Avicenne, Bobigny; INSERM, UMR S 662, Paris; Université Paris 7, IUH, UMR S 662, Paris, France. In an acute promyelocytic leukemia (APL)–transplantable mouse model, we previously reported the presence of antibodies recognizing PML-RAR and RAR in the sera of ATRA-treated mice. To evaluate this immune response, we determined the prevalence of anti-RAR antibodies in a cohort of 48 APL mice, treated by ATRA (n = 24) or by placebo pellets (n = 24), and in a preliminary subset of 9 patients with APL using a specific enzyme-linked immunosorbent assay (ELISA). In APL mice, significantly higher antibody levels were observed at the latest time points (day 48 to 58 levels superior to day 15 to 18 or day 28 to 38 levels). Antibody levels were higher in ATRA-treated mice than in placebo-treated mice and were also predictive of better survival. In the patients with APL, anti-RAR antibodies were detected at diagnosis and after maintenance therapy, reminiscent of the ATRA-treated APL mice. Antinuclear or antineutrophil cytoplasmic autoantibodies were also detected. These data reveal for the first time that in patients with APL an immune response may be detected at diagnosis and enhanced after maintenance therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020